open access

Vol 16, No 2 (2020)
Review paper
Published online: 2020-05-15
Get Citation

Encorafenib in combination with binimetinib — a new therapeutic option with a favourable safety profile in the treatment of patients with advanced BRAF mutation-positive melanoma

Paulina Jagodzińska-Mucha, Piotr Rutkowski
DOI: 10.5603/OCP.2019.0038
·
Oncol Clin Pract 2020;16(2):75-82.

open access

Vol 16, No 2 (2020)
REVIEW ARTICLES
Published online: 2020-05-15

Abstract

Encorafenib and binimetinib were registered in 2018 for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. The results of the phase III study (Columbus) are very promising. Median PFS for patients who have received this treatment was 14.9 months, and the median OS was 33.6 months. The reduction of toxicity is the reason for the unique pharmacokinetic profile of this therapy. Knowledge about the adverse evets is important in the context of optimizing and individualizing treatment.

Abstract

Encorafenib and binimetinib were registered in 2018 for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. The results of the phase III study (Columbus) are very promising. Median PFS for patients who have received this treatment was 14.9 months, and the median OS was 33.6 months. The reduction of toxicity is the reason for the unique pharmacokinetic profile of this therapy. Knowledge about the adverse evets is important in the context of optimizing and individualizing treatment.

Get Citation

Keywords

encorafenib; binimetinib; BRAF; melanoma; adverse events; safety of treatment

About this article
Title

Encorafenib in combination with binimetinib — a new therapeutic option with a favourable safety profile in the treatment of patients with advanced BRAF mutation-positive melanoma

Journal

Oncology in Clinical Practice

Issue

Vol 16, No 2 (2020)

Article type

Review paper

Pages

75-82

Published online

2020-05-15

DOI

10.5603/OCP.2019.0038

Bibliographic record

Oncol Clin Pract 2020;16(2):75-82.

Keywords

encorafenib
binimetinib
BRAF
melanoma
adverse events
safety of treatment

Authors

Paulina Jagodzińska-Mucha
Piotr Rutkowski

References (12)
  1. Colombino M, Capone M, Lissia A, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol. 2012; 30(20): 2522–2529.
  2. Hamid O, Cowey CL, Offner M, et al. Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma. Cancers (Basel). 2019; 11(11).
  3. Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014; 371(20): 1867–1876.
  4. Delord JP, Robert C, Nyakas M, et al. Phase i dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic -mutant melanoma. Clin Cancer Res. 2017; 23(18): 5339–5348.
  5. Gogas HJ, Flaherty KT, Dummer R, et al. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. Eur J Cancer. 2019; 119: 97–106.
  6. Koelblinger P, Thuerigen O, Dummer R. Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 2018; 30(2): 125–133.
  7. Adelmann CH, Ching G, Du L, et al. Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity. Oncotarget. 2016; 7(21): 30453–30460.
  8. Heinzerling L, Eigentler TK, Fluck M, et al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open. 2019; 4(3): e000491.
  9. Ascierto P, McArthur G, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016; 17(9): 1248–1260.
  10. Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018; 19(10): 1315–1327.
  11. Grob JJ, Amonkar MM, Karaszewska B, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015; 16(13): 1389–1398.
  12. Dréno B, Ribas A, Larkin J, et al. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol. 2017; 28(5): 1137–1144.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl